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Back.vound. The etkt of alteplase ww heparin in pulmo- 
nary embolism has not been studied extensiveI) wilh wial pul. 
nwnary an&rams. 
06je~tiws. ‘The aim of this randomized, open trial was to 
evaluate the eRicacy and safety of akplase fallowed by bsparin, 
versus hcparin alone, k ;U patients with angingrsphirallg docu- 
mrnted pulmonary embolism. 
Results. The vascular obstruction, assessed by [he Milk indrx 
al pulmonary angiography, decreased significantly in alleplaoe- 
[rated patients (p < 0.01) from a baseline of28.3 + 2.9 tea value 
nf24.8 f 5.2 i h a”er [be star, alinfusion; in the be@” group 
there was no change Warn 255.3 f 5.3 lo 25.2 5 5.4). Mean 
pulmonary artcry pressure decreased signiiiesntly from a barrline 
of 30.2 -C 7.8 mm Hg lo 21.4 + 6.7 in the alleplase group and 
increased in the heparin WOUD (from 22.3 + 10.5 lo 24.8 I 
In 14 of 20 akeplawtrestad padents and in 6 of 16 in the heparin 
group ,p = NSI. There were three major bleeding episc& in the 
alteplase group and two in the heparin group. Two patients died 
alter fibrinolysis (one of acute renal Bike akr cardiac tampon. 
ade and o”e of cardiac arrest after cerebra, hemorrbqe, and o”e 
patient in [be beparin group died of recurrent pubnonary embe 
:$m. 
Conclusions. Alteplase resulted in a greater and faster im. 
~m~ement ol the aneioeraobic and bemodvnamic variables com- 
pored with hep& k&r, the high irequency of bleeding 
abserwd wltb alteplase in this trial suggests that patients hould 
he carefully selected before lbrombolytic therapy is given. 
N Am Co/l Cardiol1992:2O:SZO-6) 
There is increasing evidence of the eiktiveness of alteplase 
IR-PA) m the treatmen, of acute massive pulmonary embo- 
lism: its use is widespread an the bank of the resuks of 
noncontrolled (l-3) and controlled trials in comparison wilh 
urokinm !41 and hepam (5). In the studies just cited, 
alteplare was gwen as a slow infusion or an intravenous 
bolus invctiun (6) in doses rangmg from 50 to IM) mg and 
was shown to induce eRwive clot lysis. 
Until now. only preliminary data have been rcporied (51 
comparing the eRctiveness of alteplase versus heparin 
Infusion in patients with pulmonary embolism. ThereWe. 
the present investigation was carried out to compare ,he 
ellicacy and safety of alteplaae followed by heparin wirh 
those of heparin alone. 
Methods 
This open, panllel. multicenter randomized trial was 
carried out from October 1988 lo November 1990. The 
protocol was approved by an Ethics and Data Monitoring 
Committee specifically organized for the study and by the 
Commission for Human Experimentation in each of the eight 
participating cemers. The Committee suggested that in. 
formed consent should not be required from patients. mainly 
because their condition was too critical for a satisfactory 
application of the procedure. Nevertheless. medical staff 
were ready co provide explanations to the panent and family scan5 were eraluated by two physicianr who did no: know the 
upon request. patient‘$ treatment group or the chronologjc order of the scans 
Study patients. Patients were admitted acccrding to the at a core laboratory. Pert&ion impairment ‘NBS assessed by 
following inclusion criteria: I) age between 18 and 80 years: gtving a xorc of 1 to each unperfused segmem and 0.5 10 each 
2) clinical signs and symptoms indicating pulmonary embo- poorly or partially perfused segment (81. 
lism. within 10 days of its onset; 3) confirmatory pulmonary Bleeding complications and blood coagulation tests. Major 
angiogram showing vascular obstruction >30?& corrcspond- blccdma was defined as an iowacerebral hemorrhap, con- 
ing to a Miller index score >I I 17). 
The exclusion criteria were II cardiogenic shock defined 
as s)stuItc blood pressure <90 mm Hg and xinary ou!txt 
~20 ml/h; 2) surgical procedure or organ brow tn the 
previous 7 days; 3) gastrointestinal or gemtourinary bleeding 
during the previous 3 months; 4) stroke or transient ischcmic 
attack in the previous 3 months: 5) Quncrure of noncom- 
oressible vessels; 61 uncontrolled hvpertension (diastolic 
blood pressure ~120 mn Hg. systblic blood pressure 
>2W mm He: 71 hematoloeic disorders and contramdicdtion 
to the use ofiheparin: 81 severe hepatic or renal insufficiency: 
9) QEg”a”Cy Or ktati”“. 
On hospital admission. ail patients with clinical symp- 
tarns suggesting pulmonary embolism underwent electrocar- 
diography. chest roentgcnogram. lung scan (optional). plus 
selective pulmonary aniiography of the righr and ieit pubno- 
nary arteries with determination of the pulmonary artery 
pressure and measurement of pulmonary artery oxygen. No 
s&tic recommendations for the type of catheler to be used 
t&e given. 
Treatment pmtocal. Duling the diagnostic procedure all 
patients received brpatin ltit.OCi3 IU. as an intravenous 
bolos iniection). Later. patients were randomly allocated to 
two groups, and given either I) a 2-h infusion of alleplase 
flfJ0 me IlO-ma bolus dose plus SO rn~ in h I and 40 mg in h 
i; Act&&, B-%hringer l&lheim I&? S.p.A.1 through a 
peripheral vein) followed by intravenous heparin; or 2) a 
heparin infusion. The sug8essted rate ofheperin infusion was 
1.750 l”“, for 7 10 10 days. However. ,he study Qrotocot 
recommended adjustment ofthe rate of hrparin infusion to a 
target range ofactivated partial thmmboplastin time that was 
two to three times the mean normal value Ifeach laboratory. 
Evaluatiin of angiography and lung scan. A second pul- 
monary angiogram. with measurement of Qulmonxy anery 
pressures, was performed at the end of the 2-h infusion of 
&e&se or heoarin. The oulmonary angiograms were eval- 
uated by the Miller index (?I. This index yields scow of 0 to 
34 (34 reoresents the sum of a maximal score of 16 for the 
thrombttj artd of I8 for the peripheral perfusion defects). 
Pulmonary angiograms were evaluated separately by three 
investigators who had no knowledge of treatment allocation 
and were not aware of the chronologic sequence of the two 
angiographic studies. 
When possible, perfusion lung xanz were rerfonned with 
technetium-!G9m-labeled albumin microsphere5 before and at 
7 and 30 days after patient entry into the study. Lateral views 
we acquired whenever a rectilinear seamer was used to 
perform scimigraphy; oblique projections (anterior or poste- 
rior) were taken when a planar g mma camera was used. Lung 
firmed by computed romography. or as bleeding requiring 
transfusion of one or more units of blood. Whereas hemo- 
coaguiabon v&blrs. a&ated partial thromboplartin time. 
prothrombm time and platelet count were assessed at the 
local ten-en. the D-dimer (ELISA D-dimcr. Bochnnger 
Mannhrim,. pluminogen (Plasminogen Calorimetric Tea. 
Boebrinner Mannheim) and fibrinogen IPihrinoaen Kinetics. 
Boehrmger Mannheim) were determined in a-core labora- 
tory. These variables were evaluated at baseline and at Z and 
14 h after the start of infusion of c&her aheQt&Se or heparin. 
Blood samples for routine laboratory investigations were 
obuined ar the same times. The partial thrombaplastin time 
was conrinually monitored (every 6 to I2 h) to regulate 
heparin infusion. 
Statistical considerations. Sample size was determined by 
assummg for abeplase the same efficacy shown by urokinase 
tn the Urokmare Pulmonary Embolism Trial (UPET) (9). in 
whzch the aagiographic index of severity decreased by 44% 
with urokinase and by 7% with heparin (6 = 37%). A total of 
60 patients (3Ultreatment group) was calculated to detect a 
statistically significant difference in this variable, assumtng 
two-tailed alpha = 0.05 and two-tailed beta, = 0.80. 
All tebfs used for smtistical analysis were two-tailed. 
Frequency data were analyzed bp the chisquare or Fisher 
exact test. The primary end point, the pulmonary angio- 
graphic index. was analyzed by B Student I test for unpaired 
data to test homogeneity of the basal values. by a Student r 
test for paired data and by the nested awlysis of variance 
(between-treatments and treatment by lung site). Covariance 
analysis was applied to pulmonary artery pressure, cardiac 
mde”.. Qulmonary artery oxygen and pulmonary wedge pres- 
sore, using basal vatue~ as covariates. Lung scan data were 
evaluated hy nested analysis of variance on the differences 
bw.veen the values after treatment and the baseline. Hemo- 
coagulation variables were analyzed by the Student r test for
paired data and nested analysis of variance. In the tables. 
only signtficant differences are reported. 
According. to the trial protocol. interim data for the first 
32 patients were analyzed and the results submitted to the 
Ethics and Data Monitoring Committee. rhe protocol stated 
that the inve&&m should he interrupted if interim data 
yielded a ditkrence between the two treatments >3 SD (p < 
0.01) 01 the angiographic index or a difference between the 
two treatments >2 SD (Q < 0.051 in bleeding complications. 
or both. Because the first rule was met. the Committee 
recommended premature rermination of the trial. During rhe 
period m which the data we:; being analyzed ad interim and 
the Committee had decided to stop the trial. four oiher 
patients were enrolled. Therefore, the results refer to 36 
patients. 
Results 
Patienl data (Table I). Of 36 patients, all fulfilling the 
inclusion criteria, 20 wcrc assigned to alteplase and 16 to 
hepsrin therapy. The demographic data. distribution of 
risk factors and the time from the onset of symptoms of 
pulmonary embohsm to the beginning of treatment were 
homogeneous in the two groups: the pulmonary angio- 
graphic index and mean pulmonary artery pressure values 
were greater in the alteplase gnup, but only the basal 
pulmonary artery pressure was significantly (p < 0.05) 
higher in this group, 
Angiograpbic, bemodynamic and lung scan data. In p”- 
tients who underwent fibrinolytic treatment, at the end 
of the 2-h infusion, the Miller total score (Table 2) de- 
creased (from 28.3 + 2.9 to 24.8 f 5.2 [mean 2 SD]) in 
the heparin group this value did not change (from 25.3 ‘_ 
5.3 to 25.2 + 5.4). Nested analysis of variance showed 
significant differences between the treatments in right, 
left and total lung scores. lndiwdual data are Plotted in 
Figure 1. In the alteplase group. 17 of 20 patients had 
a decrease in Ihe index of vascular obstruction: in tbe 
heparin group. angiograms indicated clot lysis in 4 of 16 
patients. 
Table 3 shows that mean pulmonary anay pressure 
decreased significantly in the altcplasc group (from 30.2 2 
7.8 to 21.4 f 6.7 mm Hg; p < 0.01). whereas it increased 
significantly in the hepar’n group (from ii.3 ? 10.5 to 24.0 + 
I I.2 mm Hg: p <’ 9.01): individual data are reported in Figure 
2. The betwen-treatment analysis of covariance. applied IO 
allow a comparison because the baselines were no1 home. 
geneous, showed a significant difference (p < 0.01) in 
pnlmonary artery pressure values (Table 3). Puimonary 
wedge prersure did not change Ggnificaatly m either trcat- 
ment group. Cardiac index increased in the alteplase group 
fmm 2.1 to 2.4 lilerdmin per m2 (p < 0.01) but remained the 
fame (2.9 literslmin per m’) (Table 3) in the heparin group. 
Although the iwrease in pulmonary artery oxygen was more 
evident after thrombolysis (alteplase, from 52.5 * 18.8 to 
61.7 + 23.8 mm Hg; hcparin, from 65.6 2 16.8 to 67 t 
14.6 mm Hg), there was no significant difference between the 
two groups (-Table 3). 
R&s from perfusion scintigraphy (Table 4) showed 
significant differences (p < 0.05) between the two groups in 
the baseline value ofright. left and total lung score. Within- 
group analysis yielded a significant decrease from baseline 
values in both groups. No di&rences between the two 
groups were found in the two follow-up lung scans. 
Table 2. Pulmonary Angiographic Score of Severi~ (Miller index) 
Belore (haselmel and AfIcr (2 h) Treatment Values 
Alle~lase + Hemrin Hemdn Alone 
Clinical events. BIeeding eppisodes ITuhks 5 atid 1) Four- 
teen of 20 alteplase-treated patients had bleeding complica- 
tions; and in 3 these were major bleeding episodes as defined 
in the protocol (2 with hemoglobin decreases 25 g/d!). Six of 
16 heparin-treated patients had a bleeding episode that was 
classified in 2 a~ a major episode. No significant difference 
between the two groups was found in the number of patients 
with bleeding evenls. Of minor bleeding events. hematomas 
at the site of catheter insertion were the most frequent in 
both groups (nine in the aheplase and four in the heparin 
group). 
hypertension (pretreatment systemic arterial pressure 
IXJUMI mm Hg) who died on day 6 of cardiac arrest after an 
intracerebral hemorrhage. The second was a 62.year old 
woman who had cardiac tamponade due to right venbicular 
aali perforation during angiography performed wth a stla 
catheter: 19 days later. she died of acute rend fSlure. The 
hemorrhage pericardial ei%urions that occurred in 3 of 36 
patients 0 in the alteplaae and I in the heparin group) were 
caued by the use of stiff catheters (Cordis Standard. ICNI cm 
7F). In the heparin group, a 74-year old woman died of 
recurrent pulmonary embolism 2 days after randomization: 
her panni thromboplastin time ranged from 37 s to a 
Table 3. Hemodynamic Variables at Baseline and at ? Haurs Table 4. Perfusion Scintigraphy: Before and After Treatmen! 
ARer Treatment Values Ibaseline and 7th and 10th days)* 
Allrplase + &pain Heparin Alone *mep,ase + aparin Hapann Alone 
Mean r SD No Mean f SD No Mean t SD No. Mean ? SD No. 
noncoagulahlc stnte. Two additional patients in the heparin 
group complained of dyapnea, suggeslive of a recurrence of 
pulmonary embolism afler 6 h and on day 8, re~pe~t~~cl~. 
One had a parual lhromboplastin lime before the episode 
HO 6. The second bad on day 8 a lung scan that did not show 
any change in perfusion from the baseline; this patient’s 
prothrombin time was 63% (Quick test) despite the admin- 
istration of oral anticoegulant agents. On day 13. a patient 
taking alteplase had a recurrence of pulmonary embolism 
documented by a positive lung scan resull. Anticoagulant 
prophylaxis at that lime was sU!l madequate (prothrombin 
time 63%). In one woman treated with alteplase, thrombosis 
involving the femoral veins bdaterally and extending to the 
inferior woo cava was diagnosed by Doppler echacardiog- 
raphy. On the same day, she had disseminated inlmvaswlar 
coagulation (fibrinogen 0.8 dlitcr. platelet couol 27,MW& 
hemoglobin IO.2 g/d1 and prothromhin lime ranging from 
45% 10 56%). Standard therapy with inlravenous antilhrom- 
bin 111 was started; the patient recovered and was discharged 
2 months later. 
Hematology. In caeh group, the hematocrit decreased 
significatly 24 h after the start of trealmenf, hut no differ- 
ence between th- two proups was observed a~ any time of 
meaurement (Tabic 7,. In two alteplane-treated patients, 
decreaw of hemoglobin >5 g/d1 were observed. 
Activated partial thromboplastin lime increased signifi- 
cantly in both groups 2 b after al1epl.w or heparin infusion, 
and were still higher at 24 h (Table 7). At 2 h, the end of the 
lylic infusion, prothrombin time had a statistically significant 
decrease in comparison with basal values. and then rose to 
the previous levels 24 h after treatment: in lhe heparin group 
no major changes in this variable were observed (Table 7). 
The core laboratory assessments of hemocaagulation 
variables are reported in Table 8. Plasma fibrinogen de- 
creased significantly (-55.5%) I the end of alteplase infu- 
sion, but no decrease was observed after 2 h of heparin 
infusion. Plasma fragment D-dimers, indicators of the occur- 
renee of a clot lysis, one than doubled after alteplase 
treatment, but did not change in patients allocated lo heparin 
(Table XL In contrast to heparin, alteplase induced a signif- 
icant decrease in free circulating plasminogen (-69.9%). 
Discussion 
Study findings. The results confirm thal alteplase leads to 
greater lysis of pulmonary clots than dots heparin Lreatmeot, 
as indicaled by the changes in Miller aogiogmphic scores. 
On admission, patients allocated to thrombolysis were in 
more critical condition than were those assigned to heparin. 
Table 8. HemoEaagulatlan Yariables a1 Basehe h”d at 2 ad 24 repro to both ihe dose. whether fixed or adjusled ior body 
Hours After Treatment weight. and ihe rate of infusion. After the encooraging 
Altrplare + Hepnnn “span” 4ione resuiis woh rerpect to vascular rep&&ion snd bleedins 
Mean t SD no. Meil” 2 SD N<. comphcations of a pilot study in subjects with venous 
Rbrinagen 
thrombocmbohc disease (15) given alteplasc as a 0.6.mdkg 
Baseh”e 1.3*19 18 5lr16 II 
holus injection. Levine and coworkers (6) administered the 
Zh !.Y f 1. 19 5.3 I I6 
24 h 
u}: came dose of atteplase fo 33 patients with acute pulmonary 
21f2.,* ,a 1,217 13 cmbotism. Their resultr indicated h greater esolution of the 
o-dimer ,&nl, perfwon defect. as assessed by lung scan. 24 h after 
F&reline 6.3 T 3.5 IS 6? T i II thrombolyci<. in the alteplase as compared with the placebo 
Zh tx7z4v 19 61Z49 II + group. No major bleeding occurred and only minor bleeding 
24h to.7 z 4.8 IX 5.4 T 42 i, I 
PlaSmIn”gen (lo) 
was rqorted for IS of the 33 patients treated with alteplare. 
Baseline 82.2 T 106 18 UI I f ?hX 
iii; 
These @ata showed that a b&s injection has considerable 
2h 25.0 f 10.6 I9 8J.3 f 19.x potenr~al for the treatment of thmmbaembolic disease. Nev- 
Nh 52.0 f tw I8 88 f I>.4 I, I enhetess. only a comparative trial with a sample size bared 
MY. 
In the alteplase group, the baseline pulmonary wiogramr Although the risk of bleeding complicrtions during and 
showed a greater involvement of pulmonary vessels. rcspon- after treatment wirh atteptase should not be mmimized, 
sible for the higher Miller index score. and greater hemody- alte~law did rerult in more effective revaiusion. Thercforc, 
namic impairment evidenced by the higher pulmonary artery 
preSSWe. 
Alteplase induced rapid lysis of the thrombi. confirme?. 
by the 2-h pulntonary angiagrams and by the hemocoagula- 
tive variables. However, the differences betwten the al- 
teplase and hepxin groups tended to narrow during the Is1 
week of treatment, as indicated by the perfusion lung scans, 
probably as consequence of rhe endogenous fibrinolysis. The 
12.4% decrease of the Miller a&graphic index tier 2-h 
infusion of 164 mg ofalteplase in this trial is comparable with 
the 12% decrease observed in the study of Verstraete et al. 
(Z), after a 2-h infusion of 50 tog of alteplase. Unfortunately. 
a direct comparison of our results with data from the 
controlled trial comparing alteplaae and urokinaae (4) is 
difficult because of the different scoring systems adopted. 
Bktdiag complications. The frequency of bleeding com- 
plications in our study was higher in the alteplase plus 
a fibrinoly~tc treatment should be considered for the more 
compromised patients with pulmonary embolism The less 
critically ill Datients hould probably rece!w standard hep- 
win therapy until new dosage regimens of thrombolytic 
agents are proved to be safer. Evenrually. large prospective 
trials comparing alteplase and heptin are required to bal- 
ance monality. recurrence of pulmonvy embolism and other 
adverse clinical events against the hemorrhagic risk. 
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